The U.S. is successfully using the threat of trade tariffs to pressure countries like the UK into paying more for American pharmaceutical innovations. This non-traditional approach reframes the "foreign free-riding" problem in healthcare as a trade policy issue, giving the U.S. significant leverage.
The administration is applying the same logic used to compel NATO allies to increase defense spending to now pressure countries to raise pharmaceutical spending as a percentage of GDP. This strategy frames low drug reimbursement as an issue of allies not paying their "fair share" for American innovation.
Beyond broad tariff threats, the U.S. possesses a specific legal tool, Section 301, which allows the U.S. Trade Representative to formally investigate and impose targeted tariffs on countries with policies deemed unfair, such as artificially suppressing the price of innovative medicines.
The UK's agreement to increase drug spending was not solely a result of U.S. tariff threats. It was equally motivated by internal pressure, as major pharmaceutical firms like Merck, Sanofi, and AstraZeneca were divesting from the country due to its unfavorable pricing system, creating a patient access issue.
The argument against adopting lower foreign drug prices is framed as a national security imperative. Proponents argue that such price controls would slash U.S. R&D investment, allowing China to dominate the bio-pharma sector and potentially weaponize future drug supply chains in a crisis.